Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: Is drug efficacy always the same?

Pharmacological Research

Volumn 37, Issue 5, 1998, Pages 339-343

  Calabresi, Laura ^a   Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SHORT SURVEY;

EID: 0032077589     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0308     Document Type: Article

References (19)

1. 1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. Br Med J 1996; 312: 71-2.
2. 2. Cook RJ, Sackett DL. The number needed to treat: a clinically, useful measure of treatment effect. Br Med J 1995; 310: 452-4.
3. 3. Isles C, Norrie J. Coronary prevention with statins: towards evidence based decisions on the use of lipid lowering drugs. Atheroscler ID Res Alert 1997; 2: 89-94.
4. 4. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
5. 5. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351-64.
6. 6. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koshinen P, Manninen V et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
7. 7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
8. 8. Buchwald H, Varco R, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edminstan WA, Smink RD Jr, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
9. 9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. 10. Sacks MF, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-09.
11. 11. Lipid Research Clinics Program. The Lipid research clinics coronary primary prevention trial results. I. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984; 251: 365-74.
12. 12. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335: 827-38.
13. 13. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Textbook of hypertension. Oxford: Blackwell Scientific, 1994: 1150-64.
14. 14. Muls E, Pettitt D. The economics of lipid-lowering therapy: A review. Vasc Dis 1997; 2: 547-57.
15. 15. Miller DB. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Arch Int Med 1997; 157: 2045-52.
16. 16. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-aspirin reinfarction study, II: Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
17. 17. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-50.
18. 18. Assmann G. Simvastatin in the secondary prevention of coronary heart disease. Pharmacol Res 1997; 35: 161.
19. 19. Verbeugt FWA. Aspirin, the poor man's statin. Lancet 1998; 351: 227-8.